Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies

2015 ◽  
Vol 69 ◽  
pp. 51-60 ◽  
Author(s):  
Shweta Sharma ◽  
Ashwni Verma ◽  
B. Venkatesh Teja ◽  
Prashant Shukla ◽  
Prabhat Ranjan Mishra
Keyword(s):  
In Vivo Efficacy ◽  
Efficacy Studies

In Vitro and In Vivo Sequestration of Phencyclidine by Me4Cucurbit[8]uril

2020 ◽  
Author(s):  
Steven Murkli ◽  
Jared Klemm ◽  
Adam T. Brockett ◽  
Michael Shuster ◽  
Volker Briken ◽  
...  
Keyword(s):  
Drugs Of Abuse ◽  
In Vivo Efficacy ◽  
In Vitro Binding ◽  
In Vivo Assays ◽  
Vitro Binding ◽  
Efficacy Studies

This work describes the in vitro binding of CB[8] and Me4CB[8] toward a panel of 10 drugs of abuse, and in vitro and in vivo assays to demonstrate the biocompatibility of Me4CB[8]. In vivo efficacy studies show that Me4CB[8] can control the hyper locomotion of animals treated with PCP.

scholarly journals Synthesis, In Vitro Profiling, and In Vivo Efficacy Studies of a New Family of Multitarget Anti-Alzheimer Compounds

Proceedings ◽  
2019 ◽  
Vol 22 (1) ◽  
pp. 71
Author(s):  
Pérez-Areales ◽  
Garrido ◽  
Aso ◽  
Bartolini ◽  
Simone ◽  
...  
Keyword(s):  
Pathogenic Role ◽  
In Vivo Efficacy ◽  
Multifactorial Diseases ◽  
New Family ◽  
Promising Strategy ◽  
Efficacy Studies

Simultaneous modulation of several targets or pathological events with a key pathogenic role isa promising strategy to tackle thus far difficult-to-cure or incurable multifactorial diseases [...]

In Vitro and In Vivo Efficacy of a Potentiated Sulfonamide in Control of Furunculosis in Salmonids

1974 ◽  
Vol 31 (1) ◽  
pp. 75-82 ◽  
Author(s):  
G. L. Bullock ◽  
H. M. Stuckey ◽  
Diane Collis ◽  
R. L. Herman ◽  
G. Maestrone
Keyword(s):  
Causative Agent ◽  
Dosage Level ◽  
Field Trials ◽  
Aeromonas Salmonicida ◽  
Effective Control ◽  
In Vivo Efficacy ◽  
Extensive Field ◽  
Efficacy Studies

In vitro and in vivo efficacy of a potentiated sulffonamide, Ro5–0037, for inhibition of Aeromonas salmonicida, causative agent of fish furunculosis was determined. The components of the potentiated sulfonamide, sulfadimethoxine, and ormetoprim were tested alone and in combination. In vitro results showed that both sulfonamide-resistant and sensitive strains of A. salmonicida had greater sensitivity to Ro5–0037 than to either of its components. Also, sulfonamide-sensitive strains developed resistance to ormetoprim and sulfadimethoxine more rapidly than to Ro5–0037. Efficacy studies with small numbers of artificially infected trout revealed that Ro5–0037 effectively controlled furunculosis at 50 mg/kg of fish/day, one fourth the usual sulfonamide dosage level. Extensive field trials also showed the 50 mg/kg level of Ro5–0037 gave effective control of hatchery outbreaks of furunculosis. As found in the in vitro studies, all in vivo trials indicated the combination of ormetoprim and sulfadimethoxine was more efficient in inhibiting A. salmonicida than either component alone.

In Vitro and In Vivo Sequestration of Phencyclidine by Me4Cucurbit[8]uril

2020 ◽  
Author(s):  
Steven Murkli ◽  
Jared Klemm ◽  
Adam T. Brockett ◽  
Michael Shuster ◽  
Volker Briken ◽  
...  
Keyword(s):  
Drugs Of Abuse ◽  
In Vivo Efficacy ◽  
In Vitro Binding ◽  
In Vivo Assays ◽  
Vitro Binding ◽  
Efficacy Studies

This work describes the in vitro binding of CB[8] and Me4CB[8] toward a panel of 10 drugs of abuse, and in vitro and in vivo assays to demonstrate the biocompatibility of Me4CB[8]. In vivo efficacy studies show that Me4CB[8] can control the hyper locomotion of animals treated with PCP.

Novel Levetiracetam Derivatives That Are Effective against the Alzheimer-like Phenotype in Mice: Synthesis, in Vitro, ex Vivo, and in Vivo Efficacy Studies

2015 ◽  
Vol 58 (15) ◽  
pp. 6018-6032 ◽  
Author(s):  
Irene Sola ◽  
Ester Aso ◽  
Daniela Frattini ◽  
Irene López-González ◽  
Alba Espargaró ◽  
...  
Keyword(s):  
Ex Vivo ◽  
In Vivo Efficacy ◽  
Efficacy Studies

scholarly journals 865 iosH2 exerts potent anti-tumor activity by blocking LILRB1/2 and KIR3DL1 receptor signaling

2021 ◽  
Vol 9 (Suppl 3) ◽  
pp. A906-A906
Author(s):  
Osiris Marroquin Belaunzaran ◽  
Anahita Rafiei ◽  
Anil Kumar ◽  
Marco Gualandi ◽  
Magdalena Westphal ◽  
...  
Keyword(s):  
Mouse Models ◽  
Nk Cell ◽  
Rational Approach ◽  
Viral Control ◽  
In Vivo Efficacy ◽  
Anti Cancer ◽  
Anti Tumor Activity ◽  
Efficacy Studies

BackgroundTo develop novel anti-cancer therapeutics we have used a reverse rational approach and searched for human HLA class I molecules known to induce autoimmunity and long-term lasting viral control as a surrogate marker for potential anti-cancer activity. HLA-B*27 or HLA-B*57 are well known genetic factors associated with superior control of viral infections (e.g. HIV and HCV) through processes related to both adaptive and innate immunity. Here we demonstrate that the expression of an optimised HLA-B57-Fc fusion protein (iosH2) exerts anti-tumor efficacy through its multimodal inhibition of LILRB1/2 and KIR3DL1 receptors.Methods iosH2 was produced by stable expression in CHO cells and purified by standard chromatography techniques. Interaction and competition studies were performed using Bio-Layer Interferometry, ELISA, and cell-based assays. Analysis of LILRB1/2 downstream ITIM signaling was assessed using an automated western blot system. Functional cell-based assays including in vitro polarization and phagocytosis of macrophages, T cell and NK cell assays were assessed using live-cell imaging. In vivo efficacy studies were performed using syngeneic and humanized mouse models of cancer.Results iosH2 binds with nanomolar affinity to LILRB1/2 and KIR3DL1, and blocks HLA-G and ANGPTL’s binding to LILRB1/2. iosH2 reduces ITIM downstream signalling including phosphorylation of SHP1/2 and promotes conversion from M2 to M1 macrophage phenotype resulting in enhanced tumor cell phagocytosis in vitro. In addition, iosH2 increases T and NK cell cytotoxicity in co-cultures with cancer cell lines. In vivo efficacy studies demonstrate therapeutic efficacy in syngeneic C38 colon cancer mice and in BRGSF-HIS humanized PDX NSCLC mice in concert with reduction of pro-tumorigenic cytokines.Conclusions iosH2 binds to LILRB1/2 and KIR3DL1, restores immune effector cell function in vitro and demonstrates anti-tumor activity in diverse in vivo mouse models. iosH2 is a first-in-class multi-functional agent that promotes key components of the innate and adaptive immune system leading to profound anti-tumor activity. Clinical development is underway and a phase I trial in preparation.Ethics Approval1. Animal housing and experimental procedures were conducted according to the French and European Regulations and the National Research Council Guide for the Care and Use of Laboratory Animals7–8. The animal facility is authorized by the French authorities (Agreement N° B 21 231 011 EA). All animals procedures (including surgery, anesthesia and euthanasia as applicable) used in the current study (200269/ACT1 C38 SC/Ethical protocol: ONCO 1) were submitted to the Institutional Animal Care and Use Committee of Oncodesign (Oncomet) approved by French authorities (CNREEA agreement N° 91). 2. Animal welfare for this study complies with the UK Animals Scientific Procedures Act 1986 (ASPA) in line with Directive 2010/63/EU of the European Parliament and the Council of 22 September 2010 on the protection of animals used for scientific purposes. All experimental data management and reporting procedures were in strict accordance with applicable Crown Bioscience UK Guidelines and Standard Operating Procedures.

scholarly journals Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies

Oncogene ◽  
2013 ◽  
Vol 33 (4) ◽  
pp. 429-439 ◽  
Author(s):  
Y Cao ◽  
J W Marks ◽  
Z Liu ◽  
L H Cheung ◽  
W N Hittelman ◽  
...  
Keyword(s):  
Design Optimization ◽  
In Vivo Efficacy ◽  
Efficacy Studies
Sign in / Sign up

Export Citation Format

Share Document